Compare RGP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | SPRO |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 135.8M |
| IPO Year | 2006 | 2017 |
| Metric | RGP | SPRO |
|---|---|---|
| Price | $4.27 | $2.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $6.00 | $5.00 |
| AVG Volume (30 Days) | ★ 517.2K | 298.7K |
| Earning Date | 01-07-2026 | 03-26-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $506,739,000.00 | $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $0.51 |
| 52 Week High | $8.43 | $3.22 |
| Indicator | RGP | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 47.04 |
| Support Level | $4.19 | $2.10 |
| Resistance Level | $4.75 | $2.47 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 14.41 | 50.00 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.